A Phase I/II Clinical Study of an Intrathecal Combination of PD-1/VEGF Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis.
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Ivonescimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 25 Mar 2025 Planned initiation date changed from 1 Mar 2025 to 1 Sep 2025.
- 25 Mar 2025 Status changed from not yet recruiting to recruiting.
- 11 Feb 2025 New trial record